secwatch.observer — SEC 8-K summary
======================================

Issuer:     PMV Pharmaceuticals, Inc. (PMVP)
CIK:        0001699382
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0000950170-22-022919
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PMV Pharma Q3 2022 net loss widens to $54M; cash at $258.9M; PC14586 trial ongoing
--------------------------------------------------------------------------------

- Net loss for nine months ended Sep 30, 2022: $54.0M vs $39.5M YoY; cash & equivalents $258.9M (Dec 2021: $314.1M).
- R&D expenses rose to $37.0M (vs $24.3M) due to PC14586 clinical costs; G&A $18.9M (vs $15.5M).
- Enrollment continues in Phase 1/2 PYNNACLE trial of PC14586 for p53 Y220C advanced solid tumors.
- Phase 1b combo trial with Merck's KEYTRUDA on track to initiate in Q4 2022.
- Appointed Dr. Carol Gallagher to Board; brings 30 years of biotech leadership.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1699382/000095017022022919/0000950170-22-022919-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1699382/000095017022022919/pmvp-20221108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-022919

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer